Our study sheds new light onto the mechanisms of osimertinib resistance and provides a rationale for targeting CDK4/6 as a potential therapy in overcoming third‐generation EGFR‐TKIs in lung cancer treatment. This evidence concerns the gene EGFR and lung carcinoma.